IMPACTS OF COVID-19 ON THE IMMUNE, NEUROMUSCULAR, AND MUSCULOSKELETAL SYSTEMS AND REHABILITATION

Imagem de Miniatura
Arquivos
art_GREVE_IMPACTS_OF_COVID19_ON_THE_IMMUNE_NEUROMUSCULAR_AND_2020.PDF.pdf (149.22 KB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2020
DOI
SciELO
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOC BRASILEIRA MED ESPORTE
Autores
QUINTANA, Marilia
SOARES, Andre Luiz de Seixas
Citação
REVISTA BRASILEIRA DE MEDICINA DO ESPORTE, v.26, n.4, p.285-288, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The new coronavirus, which causes the infectious disease named COVID-19 by the World Health Organization (WHO), was notified in 2020 in China. The main clinical manifestations in infected patients are fever, cough and dyspnoea. These patients are prone to developing cardiac changes, diffuse myopathy, decreased pulmonary function, decreased inspiratory muscle strength, and a deterioration in functional capacity. Thus, it is expected that patients affected by COVID-19 will suffer musculoskeletal consequences as a result of the inflammatory process and loss of muscle mass caused by immobility, generating motor incapacities that are not yet quantifiable. It is important to understand the clinical implications caused by COVID-19, in order to have better rehabilitation strategies for these patients. The aim of this study was to conduct a reflective analysis of the impact of COVID-19 on the immune, neuromuscular and musculoskeletal systems, and its rehabilitation process. This is a reflexive analysis, developed in the Laboratory for the Study of Movement of the Institute of Orthopaedics' and Traumatology, at the Universidade de Sao Paulo School of Medicine, SP, Brazil. In this analysis, we reflect on the following topics related to COVID-19: immunological mechanisms, impact on the neuromuscular and musculoskeletal systems, and the rehabilitation of patients.
Palavras-chave
COVID-19, Neuromuscular manifestations, Musculoskeletal system, Exercise therapy, Immune system
URI
https://observatorio.fm.usp.br/handle/OPI/37829
Referências
  1. Applegate WB, 2020, J AM GERIATR SOC, V68, P681, DOI 10.1111/jgs.16426
  2. Arentson-Lantz EJ, 2016, J APPL PHYSIOL, V120, P965, DOI 10.1152/japplphysiol.00799.2015
  3. Ashour HM, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030186
  4. Baig AM, 2020, CNS NEUROSCI THER, V26, P499, DOI 10.1111/cns.13372
  5. BarkerDavies RM, 2020, BRIT J SPORT MED, P1
  6. Brasil [Ministerio da Saude], 2020, COR PLAT INT VIG SAU
  7. Brasil [Ministerio da Saude], 2020, B EPIDEMIOLOGICO, V2, P1
  8. Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
  9. Dantas Camila Moura, 2012, Rev. bras. ter. intensiva, V24, P173, DOI 10.1590/S0103-507X2012000200013
  10. De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329
  11. DeFelice FG, 2020, TRENDS NEUROSCI, P1
  12. Deftereos SG, 2020, HELL J CARDIOL
  13. Demangel R, 2017, J PHYSIOL-LONDON, V595, P4301, DOI 10.1113/JP273895
  14. Drey M, 2013, EXP GERONTOL, V48, P76, DOI 10.1016/j.exger.2012.05.021
  15. Dube M, 2018, J VIROL, V92, DOI 10.1128/JVI.00404-18
  16. Gutierrezocampo E, 2020, JANUARY 2020 ELSEVIE, V34
  17. Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004
  18. Herridge MS, 2016, INTENS CARE MED, V42, P725, DOI 10.1007/s00134-016-4321-8
  19. Ichiyama T, 2003, SERUM CYTOKINE CONCE, P734
  20. Johnston CL, 2011, PHYSIOTHERAPY, V97, P284, DOI 10.1016/j.physio.2010.12.001
  21. Kansagra SM, 2011, PEDIATR NEUROL, V45, P400, DOI 10.1016/j.pediatrneurol.2011.09.007
  22. Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
  23. Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
  24. Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390
  25. Kwong KCNK, 2020, J CLIN NEUROSCI, V77, P13, DOI 10.1016/j.jocn.2020.04.124
  26. Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
  27. Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
  28. Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
  29. Li YC, 2012, VIRUS RES, V163, P628, DOI 10.1016/j.virusres.2011.12.021
  30. Luo G., 2003, AM J PHYSIOL-REG I, V284, P1249
  31. Madjid M. P., 2020, JAMA CARDIOL, V10, P1
  32. Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
  33. Matsuda K, 2004, VET PATHOL, V41, P101, DOI 10.1354/vp.41-2-101
  34. McNeary L, 2020, PM&R, V12, P512, DOI 10.1002/pmrj.12369
  35. Mendez-Tellez PA, 2012, NEUROHOSPITALIST, V2, P96, DOI 10.1177/1941874412447631
  36. Mesquita TM de JC, 2016, REV BRAS SAUDE FUNC, V1, P1
  37. Min A, 2010, NIH PUBLIC ACCESS, V457, P989
  38. Min XY, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4013685
  39. Narici M, 2020, EUR J SPORT SCI, DOI 10.1080/17461391.2020.1761076
  40. Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
  41. Poulsen JB, 2012, DAN MED J, V59
  42. Radigan KA, 2019, J IMMUNOL, V202, P484, DOI 10.4049/jimmunol.1701433
  43. Rawal G, 2017, J TRANSL INTERN MED, V5, P90, DOI 10.1515/jtim-2016-0016
  44. Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062
  45. Sheehy LM, 2020, JMIR PUBLIC HEAL SUR, V6
  46. Shepherd S, 2017, NEUROHOSPITALIST, V7, P41, DOI 10.1177/1941874416663279
  47. Shi CS, 2019, CELL DEATH DISCOV, V5
  48. Stiller K, 2013, CHEST, V144, P825, DOI 10.1378/chest.12-2930
  49. Toscano, 2020, NEW ENGL J MED NEJMC, P17
  50. Tsai Li-Kai, 2005, Acta Neurol Taiwan, V14, P113
  51. Woods J, 2020, SPORT SOC, DOI 10.1080/17430437.2019.1710132
  52. Zhao HM, 2020, CHIN MED J
  53. Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5
  54. Zhou L, 2020, TRAVEL MED INFECT DI, DOI 10.1016/J.TMAID.2020

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOT
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/IOT
Artigos e Materiais de Revistas Científicas - LIM/41
Artigos e Materiais de Revistas Científicas - ODS/03